Skip to main content

Animations

MJFF Publications

6591 - 6600 of 8684 Results
Title
Year
  • Year
  • 2013
  • 2020
  • 2023
  • 2020
  • 2025
  • 2020
  • 2023
  • 2025
  • 2023
  • 2016
  • Summary Details
    RESTRICTED
    Title: 5-HT1 receptor agonists for the treatment of L-DOPA-induced dyskinesia: From animal models to clinical investigation
    Journal Name: Basal Ganglia
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.baga.2012.12.002
    Citation Count: 6
  • Summary Details
    OPEN
    Title: The Michael J. Fox Foundation’s Strategies for Accelerating Translation of LRRK2 into Therapies for Parkinson Disease
    Journal Name: Cells
    Publisher: MDPI AG
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3390/cells9081878
    Citation Count: 6
  • Summary Details
    OPEN
    Title: Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain
    Journal Name: Nature Nanotechnology
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1038/s41565-023-01419-x
    Citation Count: 76
  • Summary Details
    RESTRICTED
    Title: Ondansetron, a highly selective 5-HT3 receptor antagonist, reduces L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease
    Journal Name: European Journal of Pharmacology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.ejphar.2020.172914
    Citation Count: 21
  • Summary Details
    OPEN
    Title: Sex differences in the diagnosis latency of Parkinson's disease in Latin America
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2025.107344
    Citation Count: 0
  • Summary Details
    OPEN
    Title: Enhanced Susceptibility of PINK1 Knockout Rats to α-Synuclein Fibrils
    Journal Name: Neuroscience
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.neuroscience.2020.04.032
    Citation Count: 19
  • Summary Details
    OPEN
    Title: Letter in response to Cole-Hunter et al., 2023: What does “Parkinson’s disease mortality” mean?
    Journal Name: Environment International
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1016/j.envint.2023.107852
    Citation Count: 1
  • Summary Details
    OPEN
    Title: Identification of small molecule dimethyoxyphenyl piperazine inhibitors of alpha-synuclein fibril growth
    Journal Name: Scientific Reports
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1038/s41598-025-17658-y
    Citation Count: 0
  • Summary Details
    OPEN
    Title: A beginner’s guide into curated analyses of open access datasets for biomarker discovery in neurodegeneration
    Journal Name: Scientific Data
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s41597-023-02338-1
    Citation Count: 1
  • Summary Details
    OPEN
    Title: PREFACE: Divergent roles of ER stress in neurodegeneration and brain disorders
    Journal Name: Brain Research
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: publisher-specific-oa
    DOI - Digital Object Identifier: 10.1016/j.brainres.2016.09.014
    Citation Count: 1
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.